Acyclovir 800 mg BID for Recurrent HSV: Dosing Clarification
Acyclovir 800 mg twice daily is NOT the standard suppressive dose for recurrent HSV—you should use 400 mg twice daily for chronic suppression instead. 1, 2
Understanding the Dosing Confusion
The 800 mg BID dosing appears to be a misunderstanding of two distinct treatment regimens:
Episodic Treatment (Acute Recurrences)
- Acyclovir 800 mg twice daily for 5 days is appropriate for treating individual recurrent outbreaks 1, 2
- This is short-term therapy initiated at first sign of prodrome or lesions 1
- Treatment should not exceed 5 days for episodic recurrences 1
Chronic Suppressive Therapy (Long-term Prevention)
- Acyclovir 400 mg twice daily is the FDA-approved suppressive dose 1, 2
- This regimen reduces recurrence frequency by ≥75% in patients with frequent recurrences (≥6 episodes/year) 1
- Safety and efficacy documented for up to 6 years of continuous use 1, 3
Key Clinical Distinctions
For HIV-negative immunocompetent patients:
- Standard suppression: 400 mg BID 1, 2
- Alternative regimens: 200 mg 3-5 times daily 1
- The 800 mg BID dose is reserved only for acute herpes zoster (shingles), not genital HSV suppression 2
For HIV-positive patients:
- Valacyclovir 500 mg BID is preferred over acyclovir for suppression 4
- Higher doses may be needed due to more severe/prolonged disease 4
- Acyclovir 400 mg BID remains an acceptable alternative 4
Duration and Reassessment
After 1 year of continuous suppressive therapy, discontinuation should be discussed to reassess:
- Patient's psychological adjustment to genital herpes 1
- Current recurrence rate (frequency often decreases over time) 1
- Need for continued suppression 1
Long-term data supports safety for extended use:
- 5-year continuous therapy showed mean recurrences declining from 12.9/year pre-treatment to 0.8/year by year 5 3
- 20% of patients remained recurrence-free throughout 5 years 3
- No clinically significant acyclovir resistance emerged in immunocompetent patients 1, 3
Common Pitfalls to Avoid
Do not use 800 mg BID for chronic suppression—this is excessive and not evidence-based for HSV suppression 1, 2. The confusion likely stems from:
- Mixing up episodic treatment (800 mg BID × 5 days) with suppressive therapy (400 mg BID ongoing) 1, 2
- Confusing herpes zoster dosing (800 mg 5×/day) with genital HSV regimens 2
Monitor for treatment failure: If lesions don't resolve within 7-10 days on episodic therapy, suspect acyclovir resistance (rare in immunocompetent patients at <1%, but higher in immunocompromised) 4, 5. Obtain viral culture with susceptibility testing 4.
Renal dosing adjustments are critical: For CrCl 0-10 mL/min, reduce 400 mg BID to 200 mg every 12 hours 2. No routine lab monitoring needed unless substantial renal impairment exists 4, 2.